At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 122 enrolled

Drug / intervention

Aromatase Inhibitors (Arimidex) +5 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02995772

NCT02995772Phase 3Completed

Compare CT.gov

Preoperative Neoadjuvant Hormonal Therapy and Neoadjuvant Chemotherapy for Stage IIIB and IV Breast Cancer Patients in Dharmais National Cancer Center Hospital, Indonesia

Dharmais National Cancer Center Hospital·interventional·Posted Dec 16, 2016·Updated Jun 19, 2019

In Brief

A Phase 3 clinical trial evaluating Aromatase Inhibitors (Arimidex), Tamoxifen, and 4 other interventions for Breast Cancer. Completed, enrolled 122 participants across 1 site.

Detailed Summary

This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsBreast Cancer

CountriesIndonesia

Collaborators--

Timeline

Phase 3CompletedFinished

201220132014201520162017201820192020202120222023202420252026

Enrollment StartNov 2011

First PostedDec 2016

Primary CompletionNov 2018

TodayJul 2026

First PostedDec 16, 2016

Enrollment StartNov 1, 2011

Primary CompletionNov 1, 2018

TodayJul 2, 2026

Enrollment to primary: 7 yearsPosted 9.5 years ago